In a patient who developed a transient ischemic attack after a clot evacuation procedure and has hematuria, how should dual antiplatelet therapy be initiated?

Initiating Dual Antiplatelet Therapy After TIA in a Patient with Post-Procedural Hematuria

In this patient with TIA following clot evacuation and ongoing hematuria, you should delay dual antiplatelet therapy (DAPT) until the bleeding is controlled, then initiate aspirin 160-325 mg plus clopidogrel 300-600 mg loading doses followed by aspirin 81 mg plus clopidogrel 75 mg daily for 21-30 days, accepting that the delayed initiation reduces efficacy but is necessary given the active bleeding risk. 1

Critical Prerequisites Before Starting DAPT

Before initiating any antiplatelet therapy, you must:

• Obtain brain imaging (CT or MRI) to exclude intracranial hemorrhage from the TIA itself or as a complication of the clot evacuation procedure 1, 2
• Assess dysphagia through formal screening to determine the appropriate route of administration 1
• Verify non-cardioembolic etiology by excluding atrial fibrillation or other indications for anticoagulation 1, 2, 3

Managing the Bleeding Complication

The active hematuria creates a direct conflict between stroke prevention and bleeding risk:

• Active bleeding is a relative contraindication to DAPT initiation 1, 4
• Consult urology urgently to identify and treat the source of hematuria from the clot evacuation procedure
• Monitor hemoglobin and hematocrit to quantify bleeding severity 5
• Consider aspirin monotherapy (160-325 mg loading, then 81-325 mg daily) as a bridge if the bleeding is minor and the TIA risk is very high, as aspirin alone provides some stroke protection with lower bleeding risk than DAPT 1, 2

Timing Considerations and Lost Efficacy

The delay imposed by active bleeding significantly impacts outcomes:

• DAPT is most effective when started within 12-24 hours of symptom onset, with efficacy declining rapidly after 24 hours 1, 3, 6
• Initiation beyond 72 hours may provide minimal benefit, as the highest-risk period for recurrent stroke is the first 48-72 hours 6, 7
• Each day of delay increases recurrent stroke risk from approximately 2-4% in the first 48 hours 7

DAPT Initiation Protocol Once Bleeding Controlled

When hematuria resolves or stabilizes:

Loading Doses

• Aspirin 160-325 mg once (Canadian guidelines recommend 160 mg minimum) 1, 3
• Clopidogrel 300-600 mg once (300 mg based on CHANCE trial, 600 mg based on POINT trial) 1, 3

Maintenance Therapy

• Aspirin 81 mg daily plus clopidogrel 75 mg daily 1, 3
• Continue for exactly 21-30 days, then switch to monotherapy 1, 2, 3

Alternative Route if Dysphagia Present

• Aspirin 81 mg plus clopidogrel 75 mg via enteral tube, or aspirin 325 mg rectal suppository if enteral access unavailable 1

Bleeding Risk Monitoring During DAPT

Once DAPT is started despite recent hematuria:

• Major bleeding occurs in 0.9% with DAPT versus 0.4% with monotherapy over 21-30 days 1, 8
• The absolute increase is approximately 5 major bleeds per 1000 patients treated, while preventing 15 ischemic strokes per 1000 1
• Consider gastrointestinal protection with proton pump inhibitor given recent bleeding history 1
• Monitor for recurrent hematuria, gastrointestinal bleeding, or intracranial hemorrhage 1, 8

Risk Stratification for This Patient

Confirm this patient qualifies for DAPT:

• ABCD² score ≥4 for high-risk TIA, or NIHSS 0-3 for minor stroke 1, 2, 3
• Non-cardioembolic mechanism confirmed (no atrial fibrillation, no cardiac thrombus) 1, 2
• Symptom onset <24 hours ideally, maximum 72 hours for trial-proven benefit 1, 3, 6

Common Pitfalls to Avoid

• Do not start DAPT with active, uncontrolled bleeding—this is life-threatening and the bleeding source must be addressed first 4
• Do not extend DAPT beyond 30 days in this patient, as bleeding risk increases substantially (relative risk 2.20-2.48) without additional stroke prevention benefit 1, 8, 9
• Do not omit loading doses even with delayed initiation, as rapid platelet inhibition is still needed 1, 3
• Do not use ticagrelor-aspirin in this bleeding-prone patient—clopidogrel-aspirin has a more favorable bleeding profile 1, 2
• Do not continue DAPT if major bleeding occurs—immediately reassess and likely discontinue one or both agents 1, 4

Transition to Long-Term Therapy

After completing 21-30 days of DAPT:

• Switch to indefinite single antiplatelet therapy with aspirin 81-325 mg daily, clopidogrel 75 mg daily, or aspirin-dipyridamole 1, 2, 3
• Counsel the patient explicitly that dual therapy is temporary and must stop at 21-30 days 1

Alternative Approach if Bleeding Cannot Be Controlled

If hematuria persists beyond 72 hours from TIA onset:

• Use aspirin monotherapy (81-325 mg daily) indefinitely as DAPT initiation beyond 72 hours lacks evidence and the bleeding risk outweighs uncertain benefit 1, 2, 6
• Accept that the window for DAPT has closed and focus on aggressive risk factor modification and single antiplatelet therapy 2, 9